What is the growth forecast for the Bifidobacterium Longum Subsp. Infantis M-63 market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Bifidobacterium Longum Subsp. Infantis M-63 market?

Key drivers include rising awareness of probiotics and growing demand for infant nutrition products.

What are the challenges facing the Bifidobacterium Longum Subsp. Infantis M-63 market?

Challenges include strict regulations and high production costs, affecting market growth.

Which regions are leading the Bifidobacterium Longum Subsp. Infantis M-63 market?

North America and Europe are leading the market, driven by high demand for probiotics.

Who are the top companies in the Bifidobacterium Longum Subsp. Infantis M-63 market?

Top companies include Chr. Hansen, Danone, and Nestle, offering high-quality probiotic products.

What are the future opportunities in the Bifidobacterium Longum Subsp. Infantis M-63 market?

Future opportunities include increasing demand from emerging markets and growing awareness of probiotics.

How will technology impact the Bifidobacterium Longum Subsp. Infantis M-63 market?

Technology will improve production efficiency and product quality, driving market growth and future outlook.

What is the regulatory landscape for the Bifidobacterium Longum Subsp. Infantis M-63 market?

The regulatory landscape is strict, with regulations varying by region, affecting market growth and development.

Bifidobacterium Longum Subsp. Infantis M-63 Size, Share & Forecast Analysis 2025–2033

Bifidobacterium Longum Subsp. Infantis M-63 by Application (Food Additives, Medicines and Supplements, Feed Additives, Others), by Types (0-50 billion CFU/g, 50-100 billion CFU/g, ＞100 billion CFU/g), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 157

Forecast Period: 2026 - 2033

Market Size: $44.7 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 157

Forecast Period: 2026 - 2033

Market Size: $44.7 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Bifidobacterium Longum Subsp. Infantis M-63 Market Overview

The Bifidobacterium Longum Subsp. Infantis M-63 market refers to the industry focused on the production and application of this specific probiotic strain. As the global probiotics market continues to expand, the Bifidobacterium Longum Subsp. Infantis M-63 market size is expected to experience significant growth, driven by increasing demand for gut health supplements and fortified food products. The growth outlook for this market is promising, with a projected market forecast of $1.4 billion by 2026, growing at a CAGR of 7.5% during the forecast period of 2026-2033. Key drivers of this growth include rising awareness of probiotic benefits, advances in technology, and evolving consumer preferences. The industry expansion is expected to be shaped by factors such as regulatory environments, competitive intensity, and supply-chain dynamics.

Loading chart…

The largest region for the Bifidobacterium Longum Subsp. Infantis M-63 market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing demand for probiotic-based products in countries such as China and India. Key forces shaping the industry include technology shifts in fermentation and encapsulation, regulations governing probiotic labeling and claims, and consumer behavior trends towards preventive healthcare and wellness. As the market continues to evolve, strategic planners and business development teams must stay informed about the latest developments and trends to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	44.70 million
Revenue forecast in 2033	77.96 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mitushi Biopharma; Fengchen Group; Jiangsu Wecare Biotechnology Co.,Ltd.; Shenzhen Lefu Biotechnology Co.,Ltd.; Hebei Hongtao Bioengineering Co.,Ltd.; Shandong Junle Biotechnology Co.,Ltd.; Shandong Xinxiong Biotechnology Co.,Ltd.; Newgen Biotech; Pharm-Rx; Rajvi Enterprise; Shandong Pingao Pharmaceutical Co.,Ltd.; Shaanxi Chenming Biotechnology Co.,Ltd.; Xi'an Minglang Biotechnology Co.,Ltd.; Jiahe Biotechnology (Shanxi) Co.,Ltd.; Shaanxi Ruimao Biotechnology Co.,Ltd.; Shaanxi Baohe Biotechnology Co.,Ltd.; Shaanxi Lesent Biotechnology Co.,Ltd.; Shaanxi Shuoyang Biotechnology Co.,Ltd.; Shaanxi Mufan Biotechnology Co.,Ltd.; Xi'an An'Drong Biomedical Technology Co.,Ltd.; Shaanxi Guanchen Biotechnology Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bifidobacterium Longum Subsp. Infantis M-63 market is poised for significant growth, driven by increasing demand for probiotics and a rising awareness of gut health. The Bifidobacterium Longum Subsp. Infantis M-63 market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Increasing demand for probiotics in infant formula and pediatric nutrition, driven by a growing understanding of the importance of early life gut microbiome development

Advances in technology enabling the large-scale production of high-quality Bifidobacterium Longum Subsp. Infantis M-63 strains, supporting the expansion of the global market

Restraints2 items

Stringent regulatory requirements for the approval and labeling of probiotic products, potentially limiting the entry of new players into the Bifidobacterium Longum Subsp. Infantis M-63 market

High research and development costs associated with the discovery and commercialization of new probiotic strains, which can hinder innovation and growth in the market

Opportunities2 items

Growing interest in personalized nutrition and the potential for Bifidobacterium Longum Subsp. Infantis M-63 to be used in tailored probiotic solutions, offering opportunities for market differentiation and premium pricing

Expanding applications of Bifidobacterium Longum Subsp. Infantis M-63 beyond infant nutrition, into areas such as women's health and immune system support, which can further drive the growth forecast of the market

Challenges2 items

Maintaining the stability and viability of Bifidobacterium Longum Subsp. Infantis M-63 strains during manufacturing and storage, which is critical for ensuring product efficacy and consumer trust

Addressing the variability in individual responses to probiotics and the need for more robust clinical evidence supporting the health benefits of Bifidobacterium Longum Subsp. Infantis M-63, to strengthen market positioning and regulatory approval

Market Segmentation

Loading chart…

The Bifidobacterium Longum Subsp. Infantis M-63 market can be segmented based on application, which is a crucial aspect of Bifidobacterium Longum Subsp. Infantis M-63 segmentation. This market is primarily driven by its use in infant formula, dietary supplements, and pharmaceuticals. Each application contributes to the overall market size, with infant formula being the largest segment due to the increasing demand for probiotics in baby food products.

In terms of types, the Bifidobacterium Longum Subsp. Infantis M-63 market can be divided into [object Object] and [object Object] subtypes. These subtypes differ in their strain properties, production processes, and health benefits. Understanding the market taxonomy of these subtypes is essential to determine their individual contributions to the overall market size and growth prospects. The types segment plays a vital role in shaping the market landscape, as each subtype has its unique characteristics and applications.

Bifidobacterium Longum Subsp. Infantis M-63 Segmentation Breakdown9 items

Application

Food Additives

Medicines and Supplements

Feed Additives

Others

Types

0-50 billion CFU/g

50-100 billion CFU/g

＞100 billion CFU/g

Regional Insights

Loading chart…

The Bifidobacterium Longum Subsp. Infantis M-63 market growth is expected to vary across regions, with the largest share held by Asia Pacific, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Latin America, driven by increasing adoption of probiotics and a growing awareness of gut health.

Key drivers in North America include high demand for infant formula and probiotic supplements, significant investments in research and development, and a mature ecosystem supporting the growth of the Bifidobacterium Longum Subsp. Infantis M-63 market. In Europe, factors such as favorable policies, a strong infrastructure for production and distribution, and a high level of awareness about probiotic benefits are expected to contribute to market growth.

The Asia Pacific region is driven by a large and growing population, increasing adoption of probiotic products, and significant investments in the healthcare sector. Middle East & Africa are expected to experience growth due to improving infrastructure and a rising demand for probiotic products, although at a slower pace compared to other regions.

Competitive Landscape

The Bifidobacterium Longum Subsp. Infantis M-63 market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. The Bifidobacterium Longum Subsp. Infantis M-63 competitive landscape is characterized by key competitive levers including regulatory approvals and certifications. Global players are driving growth through strategic partnerships and expansion into new regions, while local companies focus on regional expansion and localization.

Companies in this market are adopting various strategies to differentiate themselves, including technology advancements, channel strength, and customization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. Common strategies include M&A, partnerships, and product launches. To stay competitive, companies must focus on innovation, cost advantages, and service models. The following companies are implementing these strategies:

Mitushi Biopharma: regional expansion

Fengchen Group: vertical integration

Jiangsu Wecare Biotechnology: innovation pipeline

Shenzhen Lefu Biotechnology: OEM tie-ups

Hebei Hongtao Bioengineering: local manufacturing

Shandong Junle Biotechnology: premium pricing

Key Bifidobacterium Longum Subsp. Infantis M-63 Companies21 items

Mitushi Biopharma

Fengchen Group

Jiangsu Wecare Biotechnology Co.,Ltd.

Shenzhen Lefu Biotechnology Co.,Ltd.

Hebei Hongtao Bioengineering Co.,Ltd.

Shandong Junle Biotechnology Co.,Ltd.

Shandong Xinxiong Biotechnology Co.,Ltd.

Newgen Biotech

Pharm-Rx

Rajvi Enterprise

Shandong Pingao Pharmaceutical Co.,Ltd.

Shaanxi Chenming Biotechnology Co.,Ltd.

Xi'an Minglang Biotechnology Co.,Ltd.

Jiahe Biotechnology (Shanxi) Co.,Ltd.

Shaanxi Ruimao Biotechnology Co.,Ltd.

Shaanxi Baohe Biotechnology Co.,Ltd.

Shaanxi Lesent Biotechnology Co.,Ltd.

Shaanxi Shuoyang Biotechnology Co.,Ltd.

Shaanxi Mufan Biotechnology Co.,Ltd.

Xi'an An'Drong Biomedical Technology Co.,Ltd.

Shaanxi Guanchen Biotechnology Co.,Ltd.

Market Ecosystem

The Bifidobacterium Longum Subsp. Infantis M-63 ecosystem encompasses a complex network of upstream, midstream, and downstream participants, including technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Bifidobacterium Longum Subsp. Infantis M-63 products, with various stakeholders influencing the flow of goods, services, and information. The ecosystem boundaries are defined by the interactions among these participants, shaping the overall Bifidobacterium Longum Subsp. Infantis M-63 ecosystem.

Raw material suppliers — providing bacterial strains

OEMs / manufacturers — producing probiotic products

Technology providers — developing fermentation technologies

System integrators — formulating blends and mixes

Distributors / channel partners — delivering products to market

Regulators/standards bodies — establishing safety and quality standards

End users / buyers — consuming probiotic products

The flow of value in the Bifidobacterium Longum Subsp. Infantis M-63 ecosystem is influenced by control points, such as regulatory approvals and quality standards, which can create bottlenecks and impact the adoption of products. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can influence the relationships among participants, and the ecosystem may differ by region due to varying regulatory environments and market demands, highlighting the need for a comprehensive value chain analysis to understand these complexities.

Recent Industry Insights

The Bifidobacterium Longum Subsp. Infantis M-63 industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on advancing research and development in the field. Notable mergers and acquisitions have also taken place, leading to increased consolidation and expansion of product portfolios. Furthermore, several companies have launched new products and technologies, enhancing the overall competitiveness of the market.

In addition to these developments, regulatory changes have played a crucial role in shaping the industry. A shift in consumer preferences towards probiotics and gut health has driven demand for Bifidobacterium Longum Subsp. Infantis M-63-based products. The industry has also seen notable funding rounds and expansions, with investors showing increased interest in the potential of this subspecies to address various health concerns.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Bifidobacterium Longum Subsp. Infantis M-63 market. The market attractiveness of this probiotic strain is significant due to its potential health benefits. The competitive intensity is moderate, with several key players competing for market share. Looking at the Bifidobacterium Longum Subsp. Infantis M-63 market outlook, the long-term prospects are promising, driven by growing consumer interest in probiotics. The innovation landscape is characterized by ongoing research into new applications and products. However, the demand-supply balance may be affected by factors such as regulatory changes and supply chain disruptions. Key risk factors include intense competition and fluctuations in raw material prices.

12 items

1. Executive Summary

2. Bifidobacterium Longum Subsp. Infantis M-63 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Competition by Key Manufacturers

9.1. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Bifidobacterium Longum Subsp. Infantis M-63: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Mitushi Biopharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Fengchen Group

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Jiangsu Wecare Biotechnology Co.,Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Shenzhen Lefu Biotechnology Co.,Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Hebei Hongtao Bioengineering Co.,Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Shandong Junle Biotechnology Co.,Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Shandong Xinxiong Biotechnology Co.,Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Newgen Biotech

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Pharm-Rx

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Rajvi Enterprise

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shandong Pingao Pharmaceutical Co.,Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Shaanxi Chenming Biotechnology Co.,Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Xi'an Minglang Biotechnology Co.,Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jiahe Biotechnology (Shanxi) Co.,Ltd.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Shaanxi Ruimao Biotechnology Co.,Ltd.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Shaanxi Baohe Biotechnology Co.,Ltd.

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Shaanxi Lesent Biotechnology Co.,Ltd.

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Shaanxi Shuoyang Biotechnology Co.,Ltd.

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Shaanxi Mufan Biotechnology Co.,Ltd.

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Xi'an An'Drong Biomedical Technology Co.,Ltd.

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Shaanxi Guanchen Biotechnology Co.,Ltd.

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bifidobacterium Longum Subsp. Infantis M-63 Market

Figure 4: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Drivers

Figure 5: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Challenges

Figure 6: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Trends

Figure 7: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Opportunity

Figure 8: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Restraint

Figure 9: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Value (USD Million) By Region

Figure 19: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Value (USD Million) By Region

Figure 27: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By: Regions (2032)

Figure 28: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) By Region

Figure 29: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Value (USD Million) By Region

Figure 37: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By: Regions (2032)

Figure 38: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) By Region

Figure 39: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

137 items

Table 1: Market Segmentation Analysis

Table 2: Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Value (USD Million) By Region

Table 14: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) By Region

Table 31: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Bifidobacterium Longum Subsp. Infantis M-63 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Bifidobacterium Longum Subsp. Infantis M-63 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Mitushi Biopharma Basic Information And Sales Area

Table 52: Mitushi Biopharma. Products Portfolio

Table 53: Fengchen Group Basic Information And Sales Area

Table 54: Fengchen Group. Products Portfolio

Table 55: Jiangsu Wecare Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 56: Jiangsu Wecare Biotechnology Co.,Ltd.. Products Portfolio

Table 57: Shenzhen Lefu Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 58: Shenzhen Lefu Biotechnology Co.,Ltd.. Products Portfolio

Table 59: Hebei Hongtao Bioengineering Co.,Ltd. Basic Information And Sales Area

Table 60: Hebei Hongtao Bioengineering Co.,Ltd.. Products Portfolio

Table 61: Shandong Junle Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 62: Shandong Junle Biotechnology Co.,Ltd.. Products Portfolio

Table 63: Shandong Xinxiong Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 64: Shandong Xinxiong Biotechnology Co.,Ltd.. Products Portfolio

Table 65: Newgen Biotech Basic Information And Sales Area

Table 66: Newgen Biotech. Products Portfolio

Table 67: Pharm-Rx Basic Information And Sales Area

Table 68: Pharm-Rx. Products Portfolio

Table 69: Rajvi Enterprise Basic Information And Sales Area

Table 70: Rajvi Enterprise. Products Portfolio

Table 71: Shandong Pingao Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 72: Shandong Pingao Pharmaceutical Co.,Ltd.. Products Portfolio

Table 73: Shaanxi Chenming Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 74: Shaanxi Chenming Biotechnology Co.,Ltd.. Products Portfolio

Table 75: Xi'an Minglang Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 76: Xi'an Minglang Biotechnology Co.,Ltd.. Products Portfolio

Table 77: Jiahe Biotechnology (Shanxi) Co.,Ltd. Basic Information And Sales Area

Table 78: Jiahe Biotechnology (Shanxi) Co.,Ltd.. Products Portfolio

Table 79: Shaanxi Ruimao Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 80: Shaanxi Ruimao Biotechnology Co.,Ltd.. Products Portfolio

Table 81: Shaanxi Baohe Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 82: Shaanxi Baohe Biotechnology Co.,Ltd.. Products Portfolio

Table 83: Shaanxi Lesent Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 84: Shaanxi Lesent Biotechnology Co.,Ltd.. Products Portfolio

Table 85: Shaanxi Shuoyang Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 86: Shaanxi Shuoyang Biotechnology Co.,Ltd.. Products Portfolio

Table 87: Shaanxi Mufan Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 88: Shaanxi Mufan Biotechnology Co.,Ltd.. Products Portfolio

Table 89: Xi'an An'Drong Biomedical Technology Co.,Ltd. Basic Information And Sales Area

Table 90: Xi'an An'Drong Biomedical Technology Co.,Ltd.. Products Portfolio

Table 91: Shaanxi Guanchen Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 92: Shaanxi Guanchen Biotechnology Co.,Ltd.. Products Portfolio

Table 93: Global Market Value (USD Million) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Value (USD Million) (2025-2032) By Types

Table 96: Global Market Share (%) By Types (2032)

Table 97: Global Market Volume (K) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Volume (K) (2025-2032) By Types

Table 100: Global Market Share (%) By Types (2032)

Table 101: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Value (USD Million) By Region

Table 102: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By Region (2025-2032)

Table 103: North America Market Value (USD Million) (2025-2032) By Country

Table 104: North America Market Value (USD Million) (2025-2032) By Application

Table 105: North America Market Value (USD Million) (2025-2032) By Types

Table 106: Europe Market Value (USD Million) (2025-2032) By Country

Table 107: Europe Market Value (USD Million) (2025-2032) By Application

Table 108: Europe Market Value (USD Million) (2025-2032) By Types

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 110: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 112: South America Market Value (USD Million) (2025-2032) By Country

Table 113: South America Market Value (USD Million) (2025-2032) By Application

Table 114: South America Market Value (USD Million) (2025-2032) By Types

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 116: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 118: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Volume (K) By Region

Table 119: Global Bifidobacterium Longum Subsp. Infantis M-63 Market Share (%) By Region (2025-2032)

Table 120: North America Market Volume (K) (2025-2032) By Country

Table 121: North America Market Volume (K) (2025-2032) By Application

Table 122: North America Market Volume (K) (2025-2032) By Types

Table 123: Europe Market Volume (K) (2025-2032) By Country

Table 124: Europe Market Volume (K) (2025-2032) By Application

Table 125: Europe Market Volume (K) (2025-2032) By Types

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 127: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 129: South America Market Volume (K) (2025-2032) By Country

Table 130: South America Market Volume (K) (2025-2032) By Application

Table 131: South America Market Volume (K) (2025-2032) By Types

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 133: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 135: Research Programs/Design For This Report

Table 136: Key Data Information From Secondary Sources

Table 137: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Bifidobacterium Longum Subsp. Infantis M-63 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	44.70 million
Revenue forecast in 2033	77.96 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mitushi Biopharma; Fengchen Group; Jiangsu Wecare Biotechnology Co.,Ltd.; Shenzhen Lefu Biotechnology Co.,Ltd.; Hebei Hongtao Bioengineering Co.,Ltd.; Shandong Junle Biotechnology Co.,Ltd.; Shandong Xinxiong Biotechnology Co.,Ltd.; Newgen Biotech; Pharm-Rx; Rajvi Enterprise; Shandong Pingao Pharmaceutical Co.,Ltd.; Shaanxi Chenming Biotechnology Co.,Ltd.; Xi'an Minglang Biotechnology Co.,Ltd.; Jiahe Biotechnology (Shanxi) Co.,Ltd.; Shaanxi Ruimao Biotechnology Co.,Ltd.; Shaanxi Baohe Biotechnology Co.,Ltd.; Shaanxi Lesent Biotechnology Co.,Ltd.; Shaanxi Shuoyang Biotechnology Co.,Ltd.; Shaanxi Mufan Biotechnology Co.,Ltd.; Xi'an An'Drong Biomedical Technology Co.,Ltd.; Shaanxi Guanchen Biotechnology Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing demand for probiotics in infant formula and pediatric nutrition, driven by a growing understanding of the importance of early life gut microbiome development

Advances in technology enabling the large-scale production of high-quality Bifidobacterium Longum Subsp. Infantis M-63 strains, supporting the expansion of the global market

Restraints2 items

Stringent regulatory requirements for the approval and labeling of probiotic products, potentially limiting the entry of new players into the Bifidobacterium Longum Subsp. Infantis M-63 market

High research and development costs associated with the discovery and commercialization of new probiotic strains, which can hinder innovation and growth in the market

Opportunities2 items

Challenges2 items

Maintaining the stability and viability of Bifidobacterium Longum Subsp. Infantis M-63 strains during manufacturing and storage, which is critical for ensuring product efficacy and consumer trust

Market Segmentation

Loading chart…

Bifidobacterium Longum Subsp. Infantis M-63 Segmentation Breakdown9 items

Application

Food Additives

Medicines and Supplements

Feed Additives

Others

Types

0-50 billion CFU/g

50-100 billion CFU/g

＞100 billion CFU/g

Regional Insights

Loading chart…

Competitive Landscape

Mitushi Biopharma: regional expansion

Fengchen Group: vertical integration

Jiangsu Wecare Biotechnology: innovation pipeline

Shenzhen Lefu Biotechnology: OEM tie-ups

Hebei Hongtao Bioengineering: local manufacturing

Shandong Junle Biotechnology: premium pricing

Key Bifidobacterium Longum Subsp. Infantis M-63 Companies21 items

Mitushi Biopharma

Fengchen Group

Jiangsu Wecare Biotechnology Co.,Ltd.

Shenzhen Lefu Biotechnology Co.,Ltd.

Hebei Hongtao Bioengineering Co.,Ltd.

Shandong Junle Biotechnology Co.,Ltd.

Shandong Xinxiong Biotechnology Co.,Ltd.

Newgen Biotech

Pharm-Rx

Rajvi Enterprise

Shandong Pingao Pharmaceutical Co.,Ltd.

Shaanxi Chenming Biotechnology Co.,Ltd.

Xi'an Minglang Biotechnology Co.,Ltd.

Jiahe Biotechnology (Shanxi) Co.,Ltd.

Shaanxi Ruimao Biotechnology Co.,Ltd.

Shaanxi Baohe Biotechnology Co.,Ltd.

Shaanxi Lesent Biotechnology Co.,Ltd.

Shaanxi Shuoyang Biotechnology Co.,Ltd.

Shaanxi Mufan Biotechnology Co.,Ltd.

Xi'an An'Drong Biomedical Technology Co.,Ltd.

Shaanxi Guanchen Biotechnology Co.,Ltd.

Market Ecosystem

Raw material suppliers — providing bacterial strains

OEMs / manufacturers — producing probiotic products

Technology providers — developing fermentation technologies

System integrators — formulating blends and mixes

Distributors / channel partners — delivering products to market

Regulators/standards bodies — establishing safety and quality standards

End users / buyers — consuming probiotic products

Recent Industry Insights

Analyst Overview

Table of Contents